|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Novartis
|
|
gptkbp:activities
|
JA K1 and JA K2 inhibitor
|
|
gptkbp:approves
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:class
|
gptkb:drug
antineoplastic agent
|
|
gptkbp:clinical_trial
|
gptkb:unknown
Phase 3
hematologic malignancies
myeloproliferative neoplasms
|
|
gptkbp:contraindication
|
active infections
severe liver impairment
hypersensitivity to ruxolitinib
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:effective_date
|
2011-11-17
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:formulation
|
film-coated tablet
|
|
gptkbp:has_ability
|
10 mg
5 mg
15 mg
20 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Jakavi
|
|
gptkbp:ingredients
|
gptkb:ruxolitinib
C17 H18 N4 O2
|
|
gptkbp:interacts_with
|
other immunosuppressants
strong CY P3 A4 inducers
strong CY P3 A4 inhibitors
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_atype_of
|
L01 X E05
|
|
gptkbp:is_monitored_by
|
liver function tests
blood counts
|
|
gptkbp:is_used_for
|
treatment of myelofibrosis
treatment of polycythemia vera
|
|
gptkbp:lifespan
|
3 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
|
|
gptkbp:packaging
|
gptkb:beer
blister pack
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:requires
|
gptkb:theorem
|
|
gptkbp:research
|
clinical trials
combination therapy
|
|
gptkbp:side_effect
|
gptkb:fandom
dizziness
headache
thrombocytopenia
increased liver enzymes
|
|
gptkbp:storage
|
store at room temperature
keep away from moisture
|
|
gptkbp:traded_on
|
gptkb:Jakavi
|